Copyright: ©Author(s) 2026.
World J Gastrointest Oncol. Nov 15, 2026; 18(11): 123385
Published online Nov 15, 2026. doi: 10.4251/wjgo.123385
Published online Nov 15, 2026. doi: 10.4251/wjgo.123385
Table 4 Univariate and multivariate Cox analysis for progression-free survival
| Characteristics | Univariate analysis | Multivariate analysis | ||
| HR (95%CI) | P value | HR (95%CI) | P value | |
| Gender (female vs male) | 1.552 (0.939-2.566) | 0.087 | 1.800 (0.891, 3.635) | 0.101 |
| Age (< 65 vs ≥ 65 years) | 0.909 (0.606-1.364) | 0.645 | ||
| Hepatitis B infection (no vs yes) | 1.246 (0.793-1.957) | 0.340 | ||
| Hepatitis C infection (no vs yes) | 0.923 (0.128-6.635) | 0.936 | ||
| Diabetes (no vs yes) | 1.484 (0.794-2.772) | 0.216 | ||
| Hypertension (no vs yes) | 0.927 (0.627-1.372) | 0.707 | ||
| Smoking (no vs yes) | 0.748 (0.501-1.117) | 0.156 | ||
| Drinking (no vs yes) | 0.762 (0.488-1.192) | 0.234 | ||
| Tumor size (≤ 5 vs > 5 cm) | 1.021 (0.618-1.688) | 0.935 | ||
| Child-Pugh class (A vs B + C) | 1.680 (0.995-2.837) | 0.052 | 1.260 (0.658-2.414) | 0.485 |
| ECOG PS (0 vs ≥ 1) | 1.171 (0.662-2.072) | 0.587 | ||
| Portal vein invasion tumor (no vs yes) | 1.210 (0.762-1.919) | 0.419 | ||
| CNLC (IIa + IIb vs IIIa + IIIb) | 1.139 (0.787-1.649) | 0.490 | ||
| ALT (≤ 50 vs > 50 IU/L) | 1.037 (0.689-1.560) | 0.863 | ||
| AST (≤ 40 vs > 40 IU/L) | 1.233 (0.840-1.810) | 0.284 | ||
| ALB (< 35 vs ≥ 35 g/L) | 0.692 (0.466-1.027) | 0.068 | 0.698 (0.425-1.176) | 0.177 |
| TBIL (≤ 23 vs > 23 μmol/L) | 0.982 (0.641-1.505) | 0.934 | ||
| AFP (< 400 vs ≥ 400 ng/mL) | 1.908 (1.285-2.834) | 0.001 | 1.749 (1.027-2.980) | 0.040 |
| INR (≤ 1.2 vs > 1.2) | 0.878 (0.380-2.026) | 0.760 | ||
| First-line ICI therapy (no vs yes) | 1.344 (0.915-1.974) | 0.132 | ||
| Initial daily dose of regorafenib (< 160 vs 160 mg) | 1.020 (0.593-1.755) | 0.942 | ||
| Second-line PD-1 therapy (no vs yes) | 0.561 (0.379-0.830) | 0.004 | 0.549 (0.31-0.953) | 0.033 |
- Citation: Ma F, Zheng LY, Song DJ, Zhao ZW, Cao F, Hao WY, Qiu JQ, Lu D, Zheng JP. Regorafenib combined with programmed death inhibitor after initial treatment failure in unresectable hepatocellular carcinoma. World J Gastrointest Oncol 2026; 18(11): 123385
- URL: https://www.wjgnet.com/1948-5204/full/v18/i11/123385.htm
- DOI: https://dx.doi.org/10.4251/wjgo.123385